Runben Biotechnology (SH:603193) Guoyuan Securities·2024-08-16 07:37Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook on its stock performance relative to the benchmark index [5][10]. Core Insights - The company reported a significant revenue growth of 28.47% year-on-year, reaching 744 million yuan in the first half of 2024, with a net profit increase of 50.69% to 180 million yuan [3]. - The gross margin improved to 58.64%, up by 3.09 percentage points, while the net margin rose to 24.2%, an increase of 3.57 percentage points [3]. - The company has focused on optimizing its product structure, leading to an increase in average prices across its product lines, particularly in mosquito repellent and baby care products [4]. - The company launched over 50 new products in the first half of 2024, targeting differentiated market segments [4]. Financial Performance - For the first half of 2024, the company achieved a revenue of 744 million yuan, with a year-on-year growth of 28.47% [3]. - The net profit for the same period was 180 million yuan, reflecting a 50.69% increase compared to the previous year [3]. - The company’s gross margin for the first half of 2024 was 58.64%, which is an improvement of 3.09 percentage points year-on-year [3]. - The projected net profits for 2024, 2025, and 2026 are estimated at 320 million yuan, 399 million yuan, and 499 million yuan, respectively [5]. Product Performance - The mosquito repellent segment generated 331 million yuan in revenue in the first half of 2024, with a 9.64% increase in average price [4]. - The baby care segment achieved 292 million yuan in revenue, with a 23.48% increase in average price [4]. - The essential oil segment reported 108 million yuan in revenue, with a 4.45% increase in average price [4]. Market Position - The company's brand "Runben" ranked first in the mother and baby care product category during major sales events on platforms like Tmall, JD, and Pinduoduo [4]. - The company is expected to continue launching high-quality, cost-effective products in niche markets, supported by a rich pipeline of new products for the second half of 2024 [4].